de Barclays Teva Pharmaceutical Industries Limited TEVA Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Vender |
-1,343,554
| Cerradas | -USD 45.5 M | – | 5713 |
|
|
2026
Q2 | USD 45.5 M | Vender |
1,343,554
-57,117
| -4% | -USD 1.9 M | 0.01% | 771 |
|
|
2026
Q1 | USD 42.2 M | Comprar |
1,400,671
+5,000
| +0.4% | +USD 161 k | 0.01% | 792 |
|
|
2025
Q4 | USD 43.6 M | Comprar |
1,395,671
+720,545
| +107% | +USD 17.8 M | 0.01% | 846 |
|
|
2025
Q3 | USD 13.6 M | Comprar |
675,126
+75,112
| +13% | +USD 1.32 M | ﹤0.01% | 1450 |
|
|
2025
Q2 | USD 10.1 M | Vender |
600,014
-163,832
| -21% | -USD 2.64 M | ﹤0.01% | 1580 |
|
|
2025
Q1 | USD 11.7 M | Comprar |
763,846
+440,350
| +136% | +USD 7.87 M | ﹤0.01% | 1296 |
|
|
2024
Q4 | USD 7.13 M | Vender |
323,496
-104,099
| -24% | -USD 1.89 M | ﹤0.01% | 1845 |
|
|
2024
Q3 | USD 7.71 M | Comprar |
427,595
+102,848
| +32% | +USD 1.8 M | ﹤0.01% | 1684 |
|
|
2024
Q2 | USD 5.28 M | Vender |
324,747
-373,257
| -53% | -USD 5.75 M | ﹤0.01% | 1497 |
|
|
2024
Q1 | USD 9.8 M | Vender |
698,004
-303,177
| -30% | -USD 3.82 M | ﹤0.01% | 1399 |
|
|
2023
Q4 | USD 10.5 M | Vender |
1,001,181
-117,021
| -10% | -USD 1.09 M | ﹤0.01% | 1485 |
|
|
2023
Q3 | USD 11.4 M | Comprar |
1,118,202
+69,502
| +7% | +USD 647 k | 0.01% | 947 |
|
|
2023
Q2 | USD 7.9 M | Vender |
1,048,700
-736,245
| -41% | -USD 5.97 M | 0.01% | 1088 |
|
|
2023
Q1 | USD 15.8 M | Comprar |
1,784,945
+782,101
| +78% | +USD 7.73 M | 0.01% | 958 |
|
|
2022
Q4 | USD 9.15 M | Comprar |
1,002,844
+128,177
| +15% | +USD 1.12 M | ﹤0.01% | 1248 |
|
|
2022
Q3 | USD 7.06 M | Comprar |
874,667
+262,338
| +43% | +USD 2.32 M | 0.01% | 990 |
|
|
2022
Q2 | USD 4.6 M | Comprar |
612,329
+216,984
| +55% | +USD 1.89 M | ﹤0.01% | 1390 |
|
|
2022
Q1 | USD 3.71 M | Vender |
395,345
-750,574
| -65% | -USD 6.26 M | ﹤0.01% | 1413 |
|
|
2021
Q4 | USD 9.18 M | Vender |
1,145,919
-199,367
| -15% | -USD 1.8 M | ﹤0.01% | 1312 |
|
|
2021
Q3 | USD 13.1 M | Vender |
1,345,286
-74,233
| -5% | -USD 695 k | 0.01% | 1053 |
|
|
2021
Q2 | USD 14.1 M | Comprar |
1,419,519
+607,253
| +75% | +USD 6.43 M | 0.01% | 1051 |
|
|
2021
Q1 | USD 9.37 M | Vender |
812,266
-59,505
| -7% | -USD 682 k | 0.01% | 1118 |
|
|
2020
Q4 | USD 8.41 M | Comprar |
871,771
+104,286
| +14% | +USD 999 k | ﹤0.01% | 1236 |
|
|
2020
Q3 | USD 6.92 M | Comprar |
767,485
+42,394
| +6% | +USD 448 k | ﹤0.01% | 1213 |
|
|
2020
Q2 | USD 8.94 M | Vender |
725,091
-623,149
| -46% | -USD 7.05 M | 0.01% | 1034 |
|
|
2020
Q1 | USD 12.1 M | Vender |
1,348,240
-1,228,884
| -48% | -USD 12.6 M | 0.01% | 886 |
|
|
2019
Q4 | USD 25.3 M | Comprar |
2,577,124
+1,403,587
| +120% | +USD 12.5 M | 0.01% | 830 |
|
|
2019
Q3 | USD 8.07 M | Vender |
1,173,537
-371,900
| -24% | -USD 2.85 M | 0.01% | 1461 |
|
|
2019
Q2 | USD 14.3 M | Comprar |
1,545,437
+304,293
| +25% | +USD 3.67 M | 0.01% | 1128 |
|
|
2019
Q1 | USD 19.5 M | Comprar |
1,241,144
+20,190
| +2% | +USD 356 k | 0.01% | 868 |
|
|
2018
Q4 | USD 18.8 M | Vender |
1,220,954
-152,778
| -11% | -USD 3.13 M | 0.01% | 784 |
|
|
2018
Q3 | USD 29.6 M | Comprar |
1,373,732
+288,537
| +27% | +USD 6.7 M | 0.02% | 655 |
|
|
2018
Q2 | USD 26.4 M | Vender |
1,085,195
-186,006
| -15% | -USD 3.79 M | 0.02% | 644 |
|
|
2018
Q1 | USD 21.7 M | Vender |
1,271,201
-1,255,294
| -50% | -USD 24.5 M | 0.02% | 807 |
|
|
2017
Q4 | USD 47.9 M | Comprar |
2,526,495
+1,028,094
| +69% | +USD 15.5 M | 0.04% | 429 |
|
|
2017
Q3 | USD 26.4 M | Comprar |
1,498,401
+216,317
| +17% | +USD 4.87 M | 0.03% | 548 |
|
|
2017
Q2 | USD 42.6 M | Vender |
1,282,084
-440,865
| -26% | -USD 13.6 M | 0.05% | 323 |
|
|
2017
Q1 | USD 55.3 M | Comprar |
1,722,949
+596,713
| +53% | +USD 20.4 M | 0.06% | 228 |
|
|
2016
Q4 | USD 40.8 M | Comprar |
1,126,236
+662,482
| +143% | +USD 26.5 M | 0.04% | 326 |
|
|
2016
Q3 | USD 21.3 M | Vender |
463,754
-2,723,181
| -85% | -USD 142 M | 0.02% | 525 |
|
|
2016
Q2 | USD 160 M | Comprar |
3,186,935
+2,311,490
| +264% | +USD 123 M | 0.21% | 68 |
|
|
2016
Q1 | USD 46.4 M | Comprar |
875,445
+115,072
| +15% | +USD 6.75 M | 0.07% | 240 |
|
|
2015
Q4 | USD 49.4 M | Vender |
760,373
-52,748
| -6% | -USD 3.26 M | 0.06% | 283 |
|
|
2015
Q3 | USD 45.5 M | Vender |
813,121
-103,881
| -11% | -USD 6.74 M | 0.05% | 306 |
|
|
2015
Q2 | USD 54.1 M | Comprar |
917,002
+265,226
| +41% | +USD 16.4 M | 0.06% | 269 |
|
|
2015
Q1 | USD 40.4 M | Vender |
651,776
-46,101
| -7% | -USD 2.68 M | 0.05% | 391 |
|
|
2014
Q4 | USD 39.8 M | Vender |
697,877
-762,887
| -52% | -USD 42.5 M | 0.04% | 431 |
|
|
2014
Q3 | USD 77.4 M | Comprar |
1,460,764
+208,823
| +17% | +USD 11.1 M | 0.07% | 213 |
|
|
2014
Q2 | USD 65.1 M | Vender |
1,251,941
-702,852
| -36% | -USD 35.9 M | 0.07% | 239 |
|
|
2014
Q1 | USD 102 M | Comprar |
1,954,793
+438,332
| +29% | +USD 20.3 M | 0.12% | 146 |
|
|
2013
Q4 | USD 60.7 M | Comprar |
1,516,461
+333,728
| +28% | +USD 13.1 M | 0.06% | 280 |
|
|
2013
Q3 | USD 43.8 M | Comprar |
1,182,733
+365,119
| +45% | +USD 14.2 M | 0.05% | 335 |
|
|
2013
Q2 | USD 32 M | Comprar |
+817,614
| Nuevas | +USD 31.8 M | 0.04% | 416 |
|
Otros fondos que tienen TEVA en su cartera
Posición de Barclays en TEVA: resumen de T3 2026
Barclays cerró por completo su posición en Teva Pharmaceutical Industries Limited (TEVA) en T3 2026, liquidando una posición de 1,343,554 acciones por un valor estimado de USD 45.5 M.
Barclays reportó por primera vez una posición en TEVA en T2 2013 y la mantuvo durante 53 trimestres. La posición alcanzó su máximo de USD 160 M en T2 2016. Al cierre de T3 2026, 288 fondos que sigue Wall St. Rank mantienen una posición en TEVA.
- Barclays reportó que ya no tenía una posición en Teva Pharmaceutical Industries Limited al cierre de T3 2026, después de venderla por completo durante el trimestre.
- Barclays vendió 1,343,554 acciones de Teva Pharmaceutical Industries Limited en T3 2026, por un valor estimado de USD 45.5 M.
- Barclays reportó por primera vez una posición en Teva Pharmaceutical Industries Limited en T2 2013 y la mantuvo durante 53 trimestres.
- La posición de Barclays en Teva Pharmaceutical Industries Limited alcanzó su máximo de USD 160 M en T2 2016.
- Al cierre de T3 2026, 288 fondos que sigue Wall St. Rank tenían Teva Pharmaceutical Industries Limited en cartera.
Según el Informe 13F de Barclays correspondiente a T3 2026, presentado el 6 nov 2026.